Skip to main content
APVO logo

APVO · Aptevo Therapeutics Inc. · Investor Relations

Track APVO — free
$0.40 -0.01 (-3.36%)
Market Cap
$1.43M
Shares
3.46M
Volume · Nov 20 95.64K Avg daily vol (3M) 130.94K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-16 Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results
2026-11-12 Aptevo Therapeutics Announces Closing of Existing Warrants Exercise for $3.0 Million Gross Proceeds
2026-11-11 Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds
2026-11-09 Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors
2026-11-05 Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML
2026-10-26 Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant
2026-10-14 Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
2026-09-24 Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
2026-09-03 Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
2026-08-14 Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
2026-08-13 Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
2026-08-13 Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
2026-07-27 Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
2026-06-30 Aptevo Secures $1.5 Million Non-Dilutive Research Grant from the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
2026-05-27 Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
2026-05-13 Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
2026-05-06 Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
2026-03-26 Aptevo Provides State of the Business Report and 2025 Financial Results
2026-03-11 Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
2026-01-09 Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
2025-11-06 Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

Past events

Source: https://aptevotherapeutics.gcs-web.com/

Key facts CIK 1671584 CUSIP 03835L702 13F (30d) 14 filings 12 filers Visit website Investor relations